Literature DB >> 12427305

Insect cells as a factory to produce adeno-associated virus type 2 vectors.

Masashi Urabe1, Chuantian Ding, Robert M Kotin.   

Abstract

Recombinant adeno-associated viruses (rAAV) are produced transiently in mammalian cells usually by cotransfecting two or three plasmids containing AAV genes, adenovirus helper genes, and a vector genome. Expansion and transfection of adherent cells limit the scale of rAAV production. Efficient transfection is performed with cells on solid support media such as tissue culture plates. A large animal study or a human clinical trial may require 10(15) particles of vector, depending on dose. To generate this quantity of rAAV by transfection, more than 10(11) HEK293 cells may be needed, which would require about 5000 x 175 cm(2) flasks. The ability to scale up rAAV production by these methods severely restricts the commercialization and use of AAV vectors. A recombinant baculovirus derived from the Autographa californica nuclear polyhedrosis virus is widely employed for large-scale production of heterologous proteins in cultured insect cells and may provide an attractive alternative. Toward this goal, we have explored the production of rAAV in invertebrate cells. Sf9 cells may be coinfected in suspension cultures with three recombinant baculoviruses (a Rep-baculovirus, a VP-baculovirus, and an AAV ITR vector genome baculovirus) and, 3 days later, rAAV is recovered. The particles produced are indistinguishable from 293 cell-produced rAAV, as determined on the basis of physical properties and biologic activities. Particles produced by either method were composed of similar proteins and nucleic acid. The yield of genome-containing particles produced per Sf9 cell approached 5 x 10(4), thus, 1000 ml of cultured Sf9 cells produced the equivalent of between 500 to 1000 x 175 cm(2) flasks of 293 cells. This robust system provides a simple, cost-effective method for AAV vector production.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12427305     DOI: 10.1089/10430340260355347

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  168 in total

1.  Identification of the heparin binding site on adeno-associated virus serotype 3B (AAV-3B).

Authors:  Thomas F Lerch; Michael S Chapman
Journal:  Virology       Date:  2011-12-09       Impact factor: 3.616

2.  Effects of A-CREB, a dominant negative inhibitor of CREB, on the expression of c-fos and other immediate early genes in the rat SON during hyperosmotic stimulation in vivo.

Authors:  Daniel Lubelski; Todd A Ponzio; Harold Gainer
Journal:  Brain Res       Date:  2011-10-26       Impact factor: 3.252

3.  Examining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5.

Authors:  Carole E Harbison; Wendy S Weichert; Brittney L Gurda; John A Chiorini; Mavis Agbandje-McKenna; Colin R Parrish
Journal:  J Gen Virol       Date:  2011-11-09       Impact factor: 3.891

Review 4.  Gene therapy for the treatment of chronic peripheral nervous system pain.

Authors:  William F Goins; Justus B Cohen; Joseph C Glorioso
Journal:  Neurobiol Dis       Date:  2012-06-02       Impact factor: 5.996

5.  Structure of AAV-DJ, a retargeted gene therapy vector: cryo-electron microscopy at 4.5 Å resolution.

Authors:  Thomas F Lerch; Jason K O'Donnell; Nancy L Meyer; Qing Xie; Kenneth A Taylor; Scott M Stagg; Michael S Chapman
Journal:  Structure       Date:  2012-06-21       Impact factor: 5.006

6.  Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease.

Authors:  Ryan L Boudreau; Ryan M Spengler; Beverly L Davidson
Journal:  Mol Ther       Date:  2011-09-27       Impact factor: 11.454

Review 7.  Progress and challenges in viral vector manufacturing.

Authors:  Johannes C M van der Loo; J Fraser Wright
Journal:  Hum Mol Genet       Date:  2015-10-30       Impact factor: 6.150

8.  A versatile adeno-associated virus vector producer cell line method for scalable vector production of different serotypes.

Authors:  Zhenhua Yuan; Chunping Qiao; Peiqi Hu; Juan Li; Xiao Xiao
Journal:  Hum Gene Ther       Date:  2011-03-18       Impact factor: 5.695

9.  Successful production of pseudotyped rAAV vectors using a modified baculovirus expression system.

Authors:  Erik Kohlbrenner; George Aslanidi; Kevin Nash; Stanislav Shklyaev; Martha Campbell-Thompson; Barry J Byrne; Richard O Snyder; Nicholas Muzyczka; Kenneth H Warrington; Sergei Zolotukhin
Journal:  Mol Ther       Date:  2005-10-06       Impact factor: 11.454

10.  RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1.

Authors:  Megan S Keiser; James C Geoghegan; Ryan L Boudreau; Kim A Lennox; Beverly L Davidson
Journal:  Neurobiol Dis       Date:  2013-04-10       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.